Modern vaccine design has sought a minimalization approach, moving to the isolation of
antigens from pathogens that invoke a strong neutralizing immune response. This approach …

Malaria is a mosquito-borne disease caused by protozoan parasites of the genus
Plasmodium. Despite significant declines in malaria-attributable morbidity and mortality over …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

Summary Pfs230 domain 1 (Pfs230D1) is an advanced malaria transmission-blocking
vaccine antigen demonstrating high functional activity in clinical trials. However, the …

BACKGROUND Vaccines that block human-to-mosquito Plasmodium transmission are
needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for …

Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …

Background Malaria transmission-blocking vaccines target mosquito-stage parasites and
will support elimination programmes. Gamete vaccine Pfs230D1-EPA/Alhydrogel induced …

Introduction Transmission-blocking vaccines (TBV) prevent community spread of malaria by
targeting mosquito sexual stage parasites, a life-cycle bottleneck, and will be used in …

The efficient spread of malaria from infected humans to mosquitoes is a major challenge for
malaria elimination initiatives. Gametocytes are the only Plasmodium life stage infectious to …

Malaria—a parasite vector-borne disease—is a global health problem, and Plasmodium
falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in …